News & Events

Atara Biotherapeutics Announces Appointment of Cell & Gene Therapy Expert Maria Grazia Roncarolo, MD to Board of Directors

May 11, 2020

Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with severe diseases including solid tumors, hematologic cancers and autoimmune diseases, today announced the appointment of immunology and cell & gene therapy expert Maria Grazia Roncarolo, MD, to the Board of Directors.

FDA Continues Strong Support of Innovation in Development of Gene Therapy Products

January 28, 2020

This is a pivotal time in the field of gene therapy as the FDA continues its efforts to support innovators developing new medical products for Americans and others around the world. To date, the FDA has approved four gene therapy products, which insert new genetic material into a patient’s cells. The agency anticipates many more approvals in the coming years, as evidenced by the more than 900 investigational new drug (IND) applications for ongoing clinical studies in this area. The FDA believes this will provide patients and providers with increased therapeutic choices.

Stanford LCGM hosts Santa Clara High School BioTech class

Spring 2019

In early Spring 2019, Stanford University’s Laboratory for Cell and Gene Therapy hosted a BioTech class from Santa Clara High School for a day of fun, science, and career exploration!  

Proceedings of the first academic symposium on developing, qualifying
and operating a cell and gene therapy manufacturing facility

July 26, 2018

In March 2018, Stanford University’s Laboratory for Cell and Gene Therapy held a symposium with the leaders and staff of more than 25 similar facilities to discuss the collective experience in developing, qualifying and operating cell and gene therapy manufacturing facilities according to current Good Manufacturing Practices. We summarize here the findings of this inaugural meeting with an emphasis on best practices and suggested guidelines for operations.


Detection of Replication Competent Lentivirus Using a qPCR Assay for VSV-G

September 21, 2017

The Laboratory for Cell and Gene Medicine is pleased to annouce that it's first publication is now visible online. 

Stanford's Laboratory for Cell and Gene Medicine aims to ‘Cure the Incurable’

December 28, 2016

Opened in September, the 25,000-square-foot facility is currently attacking a number of the world’s most challenging medical problems. As laboratory director Dr. David DiGiusto puts it, it’s all about “curing the incurable.”

Read More

Laboratory for Cell and Gene Medicine opens in Palo Alto

September 18, 2016

Stanford’s Laboratory for Cell and Gene Medicine (LCGM), the university’s first manufacturing facility specifically designed to adhere to the Food and Drug Administration’s (FDA’s) current good manufacturing practices (CGMPs), opened this month in Palo Alto.

Stanford manufactures gene-engineered cells to cure the incurable

December 17, 2016

Inside “clean rooms” of Stanford University’s fledgling Laboratory for Cell and Gene Medicine, lab techs tend machines that churn out gene-engineered cells, which can attack cancer, fix blood disease, patch a heart, alter the immune system, build skin grafts and create a realm of yet-to-be discovered therapies.

Stanford lab grows cornea cells for transplant

April 15, 2016

Millions of new eye cells are being grown in a Palo Alto lab, enlisting one of medicine’s most important and promising new tools: refurbishing diseased and damaged tissue with healthy new cells.